Roivant Sciences (ROIV) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Business model and structure

• Operates as a therapeutic-agnostic drug developer, acquiring and developing programs in capital-efficient ways.

• Programs are housed in independent entities called "vants," most of which are wholly owned, some partially owned.

• Focuses on extracting late-stage assets from big pharma, leveraging flexibility in ownership and deal structure.

• Notable past deal: acquired and sold an anti-TL1A antibody from Pfizer to Roche for ~$7 billion.

• Maintains about $6 billion in cash, enabling pursuit of new opportunities.

Key programs and pipeline updates

• Immunovant's FcRn franchise includes batoclimab (first-generation) and 1402 (next-generation), both offering deep IgG suppression.

• 1402 is positioned as the lead due to a cleaner analyte profile, avoiding albumin and LDL impact.

• Batoclimab is in phase III for myasthenia gravis, late-stage for CIDP and TED, with upcoming data releases.

• Vtama, a topical for psoriasis, is commercially launched and awaiting atopic dermatitis approval, with potential for significant market expansion.

• Brepocitinib targets orphan rheumatology/immunology indications, focusing on white space rather than crowded markets.

• Namilumab, an anti-GM-CSF antibody for sarcoidosis, will have phase II data later this year.

Competitive landscape and strategy

• FcRn space is competitive, with J&J and argenx as key players; 1402 aims to differentiate via deeper IgG suppression and sub-Q delivery.

• Upcoming MG data for batoclimab expected to validate the "deeper is better" hypothesis for IgG suppression.

• Phase II data in various indications can rapidly inform pivotal programs, keeping the pipeline competitive.

• Vtama faces challenges in shifting physician habits from corticosteroids but is positioned as a safer, more potent topical.